Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy Academic Article uri icon

Overview

MeSH Major

  • Anthracyclines
  • Antineoplastic Agents
  • Breast Neoplasms
  • Epothilones

abstract

  • Ixabepilone is efficacious and has a predictable and manageable safety profile in women with MBC previously treated with an adjuvant anthracycline.

publication date

  • August 10, 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2006.09.7535

PubMed ID

  • 17606972

Additional Document Info

start page

  • 3415

end page

  • 20

volume

  • 25

number

  • 23